Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-21
2007-08-21
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S179000, C514S914000
Reexamination Certificate
active
10639972
ABSTRACT:
The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.
REFERENCES:
patent: 6001885 (1999-12-01), Vega et al.
Marcus, D. et al., “Carotenoid-Mediated Retinal Delivery of Triamcinolone and Ketorolac,” Invest. Ophthalmol. Vis. Sci., vol. 47, Abstract # 3803, 2006. Also presented at Annual Meeting of Association for Research in Ophthalmology, Ft. Lauderdale, Florida May 2006, Retina Society Meeting, San Diego, CA Sep. 2005, and Macula Society Meeting, San Diego, CA Feb. 2006.
International Search Report mailed Aug. 29, 2004 corresponding to PCT /US03/25229.
Aiello LP, et al., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N Engl J Med., 331, 1480-1487, 1994.
Aiello, LP, Hypoxic regulation of vascular endothelial growth factor in retinal cells, Arch Ophthalmol, 113, 1538-1544, 1995.
Beatty, S., Macular pigment and risk for age-related macular degeneration in Subjects from a Northern European population, Invest Ophthalmol Vis Sci, 42, 439-446, 2001.
Beatty, S., The role of oxidative stress in the pathogenesis of age-related macular degeneration,Surv Opthalmol,45, 115-134, 2000.
Berendschot, Tos TJM., et al., Influence of lutein supplementation on macular pigment, assessed with two objective techniques,Invest Ophthalmol Vis Sci,41, 3322-3326 2000.
Bernstein, PS, et al., Retinal tubulin binds macular carotenoids,Invest Ophthalmol Vis Sci,38, 167-175, 1997.
Blair NP, et al., Cystoid macular edema after ocular surgery. In Albert DM, Jakobiec FA, eds.Principles and Practice of Ophthalmology.Philadephia: WB Saunders, 2080-2088, 2000.
Bone, RA, et al., Stereochemistry of the human macular carotenoids,Invest Ophthalmol Vis Sci,34, 2033-2040, 1993.
Bone, RA et al., Preliminary identification of the human macular pigment,Vision Res,25, 1531-1535, 1985.
Bone, RA, et al., Distribution of lutein and zeaxanthin stereoisomers in the human retina,Acad Press,44, 211-218, 1997.
Bone, RA, et al., Lutein and zeaxanthin in the eyes, serum and diet of human subjects,Experimental Eye Research,71, 239-245, 2000.
Cooperwood, JS, et al., Nucleoside and nucleotide prodrugs, InRecent Advances in Nucleosides: Chemistry and Chemotherapy,CK Chu, ed, 91-147, 2002.
Doft BH, The endophthalmitis vitrectomy study,Arch Ophthalmol, 109, 487-488, 1991.
Flach, AJ, et al., Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine,Am J Opthalmol,112, 514-519, 1991.
Flach, AJ, et al., Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema,Am J Ophthalmol, 103, 479-486, 1987.
Fung, WE, Vitrectomy for chronic aphakic cystoid macular edema. Results of a national, collaborative, prospective, randomized investigation,Ophthalmology,92, 1102-1111, 1985.
Goodwin, TW. Metabolism, nutrition, and function of carotenoids,Ann Rev Nutr., 6, 273-297, 1986.
Guex-Crosier Y, The pathogenesis and clinical presentation of macular edema in inflammatory diseases,Doc Ophthalmol, 97, 93-105, 1999.
Hammond, Br, et al., Iris color and macular pigment optical density,Exp Eye Res.62, 293-7 1996.
Hammond, Br, et al., Dietary modification of human macular pigment density,Invest Ophthalmol Vis Sci,38, 1795-1801, 1997.
Jampol, LM, et al., Antioxidants and zinc to prevent progression of age-related macular degeneration,JAMA,286 (19), 2466-2468, 2001.
Johnson, EJ, et al., Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density,Am J Clin Nutr.,71, 1555-1562, 2000.
Kapan, LA, et al., Carotenoid composition, concentrations, and relationships in various human organs,Chin Physiol Biochem,8, 1-10, 1990.
Kliffen M, et al., Increased expression of angiogenic growth factors in age-related maculopathy,Br J Ophthalmol,81, 154-162, 1997.
Landrum, JT, et al., A one year study of the macular pigment: The effect of 140 days of a lutein supplement. Exp Eye Res., 64, 311-316, 1997.
Landrum, JT, et al., The macular pigment: a possible role in protection from age-related macular degeneration.Adv Pharmacol,38, 537-556, 1997.
Leung, IYF, et al., Absorption and tissue distribution of zeaxanthin and lutein in rhesus monkeys after taking fructus lycii (Gou Qi Zi) Extract,Invest Ophthalmol Vis Sci,42, 466-471, 2001.
Lumbroso, L., et al., Chemothermotherapy in the management of retinoblastoma,Ophthalmology, 109, 1130-1136, 2002.
Mares-Perlman, JA, et al., Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey,Am J Epidemiol,153, 424-432, 2001.
Pendergast SD et al., Vitrectomy for chronic pseudophakic cystoid macular edema,Am J Ophthalmol,128, 317-323, 1999.
Pratt, S., Dietary prevention of age-related macular degeneration,J Am Optom Assoc.,70, 39-47, 1999.
Schalch, W., Carotenoids in the retina—A review of their possible role in preventing or limiting damage caused by light and oxygen. InFree Radicals and Aging,280-298, 1992.
Seddon, JM, et al., Dietary carotenoids, vitamins A, C, and E and advanced age-related macular degeneration,JAMA,272, 1413-1420, 1994.
Seo MS, et al., Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor,Amer J Pathology,154, 1743-1753, 1999.
Shih SC, et al., Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells,J Biol Chem,274(22), 15407-15414, 1999.
Sommerburg, O., et al., Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes,Br J Ophthalmol. 82, 907-910, 1998.
Snodderly, DM, Evidence for protection against age-related macular degneration by carotenoids and antioxidant vitamins,AM j Clin Nutr.,62 (suppl.), 1448S-14461S.
Sujak, A., et al., Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects,Arch Biochem and Biophys,371, 301-307, 1999.
Toyoda, Y., et al., Effect of dietary zeaxanthin on tissue distribution of zeaxanthin and lutein in Quail,Invest Ophthalmol Vis. Sci., 43, 1210-1221, 2002.
Yoshiji H., Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis, Cancer Res (1999), 59, 4413-4418.
www.eyetk.com, Lead compound, Aptamers,Eye Tech Pharmaceuticals,3 pages, 2003.
www.macular.org, Genentech announces preliminary positive phase Ib/II data for rhuFab V2 in age-related macular degneration (AMD), 3 pages, 2003.
Chu Chung Kwang
Marcus Dennis Michael
Badio Barbara P.
Kilpatrick & Stockton LLP
Medical College of Georgia Research Institute Inc.
University of Georgia Research Foundation Inc.
LandOfFree
Methods and compositions for treatment of macular and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of macular and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of macular and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3829309